Toxicokinetics of α-zearalenol and its masked form in rats and the comparative biotransformation in liver microsomes from different livestock and humans.

Alpha-zearalenol (α-ZEL) and its masked form α-zearalenol-14 glucoside (α-ZEL-14G) have much higher oestrogenic activity than zearalenone. Owing to very limited toxicokinetic and metabolic data, no reference points could be established for risk assessment. To circumvent it, the toxicokinetic, metabolic profiles, and phenotyping of α-ZEL and α-ZEL-14G were comprehensively investigated in this study. As a result, the plasma concentrations of α-ZEL and α-ZEL-14G were all below LOQ after oral administration, while after iv injection, both could be significantly bio-transformed into various metabolites. A complete hydrolysis of α-ZEL-14G contributed to α-ZEL overall toxicity. Additionally, 31 phase I and 10 phase II metabolites of α-ZEL, and 9 phase I and 5 phase II metabolites were identified for α-ZEL-14G. For α-ZEL, hydroxylation, dehydrogenation, and glucuronidation were the major metabolic pathways, while for α-ZEL-14G, it was deglycosylation, reduction, hydroxylation, and glucuronidation. Significant metabolic differences were observed for α-ZEL and α-ZEL-14G in the liver microsomes of rats, chickens, swine, goats, cows and humans. Phenotyping studies indicated that α-ZEL and α-ZEL-14G were mediated by CYP 3A4, 2C8, and 1A2. Moreover, the deglycosylation of α-ZEL-14G was critically mediated by CES-I and CES-II. The acquired data would provide fundamental perspectives for risk evaluation of mycotoxins and their modified forms.

Glucuronidation as a metabolic barrier against zearalenone in rat everted intestine.

Zearalenone (ZON), produced by Fusarium fungi, exhibits estrogenic activity. Livestock can be exposed to ZON orally through contaminating feeds such as cereals, leading to reproductive disorders such as infertility and miscarriage via endocrine system disruption. However, the details of ZON metabolism remain unclear, and the mechanism of its toxicity has not been fully elucidated. In this study, we investigated the kinetics of ZON absorption and metabolism in rat segmented everted intestines. ZON absorption was confirmed in each intestine segment 60 min after application to the mucosal buffer at 10 µM. Approximately half of the absorbed ZON was metabolized to α-zearalenol, which tended to be mainly glucuronidated in intestinal cells. In the proximal intestine, most of the glucuronide metabolized by intestinal cells was excreted to the mucosal side, suggesting that the intestine plays an important role as a first drug metabolism barrier for ZON. However, in the distal intestine, ZON metabolites tended to be transported to the serosal side. Glucuronide transported to the serosal side could be carried via the systemic circulation to the local tissues, where it could be reactivated by deconjugation. These results are important with regard to the mechanism of endocrine disruption caused by ZON.

Uptake of natural and synthetic estrogens by maize seedlings.

Runoff from manure-fertilized crop fields constitutes a significant source of natural estrogens (e.g., estradiol [17ß-E2] and estrone [E1]) and synthetic estrogen mimics (e.g., zeranol [α-ZAL] and zearalanone [ZAN]) in the environment. However, processes such as sorption to and uptake by plants may inhibit the environmental mobility of hormonally active compounds. Sorption to dried root tissue was assessed in batch sorption tests, and resulting sorption isotherms were nonlinear at aqueous concentrations below 0.1 µM and linear above that limit. To evaluate the role of crop plants in the environmental fate of such compounds, we exposed hydroponic solutions containing 2 µM 17ß-E2, E1, α-ZAL, or ZAN to maize seedlings. After 22 days of exposure, α-ZAL and ZAN concentrations decreased by more than 96%, and 17ß-E2 and E1 were undetectable. The decrease in α-ZAL and ZAN concentrations in maize-exposed solutions was initially slow, but the observed uptake exceeded that predicted by sorption alone within 3 d. All four estrogens were detected in root tissues at concentrations up to 0.19 µmol g(-1), with concentrations peaking after 1-3 days of exposure. Only 17ß-E2 and α-ZAL were detected in shoots, and maximum concentrations were measured after 2 days for 17ß-E2 (0.02 µmol g(-1)) and 16 days for α-ZAL (0.8 nmol g(-1)). Concentrations measured in root and shoot tissues were 82% or less than those predicted by a partition-limited uptake model, which is attributed to transformation and possibly irreversible binding processes.

Absorption and metabolism of the mycotoxin zearalenone and the growth promotor zeranol in Caco-2 cells in vitro.

SCOPE: Zearalenone (ZEN) and α-zearalanol (α-ZAL, zeranol) were studied in differentiated Caco-2 cells and in the Caco-2 Millicell® system in vitro to simulate their in vivo intestinal absorption and metabolism in humans. METHODS AND RESULTS: In addition to metabolic reduction/oxidation, extensive conjugation with glucuronic acid and sulfate of the parent compounds and their phase I metabolites was observed. The positional isomers of the glucuronides and sulfates were unambiguously identified: Sulfonation occurred specifically at the 14-hydroxyl group, whereas glucuronidation was less specific and, in addition to the preferred 14-hydroxyl group, involved the 16- and 7-hydroxyl groups. Using the Caco-2 Millicell® system, an efficient transfer of the glucuronides and sulfates of ZEN and α-ZAL and their phase I metabolites into both the basolateral and the apical compartment was observed after apical administration. The apparent permeability coefficients (P(app) values) of ZEN, α-ZAL and the ZEN metabolite α-zearalenol were determined, using an initial apical concentration of 20 µM and a permeation time of 1 h. CONCLUSION: According to the P(app) values, the three compounds are expected to be extensively and rapidly absorbed from the intestinal lumen in vivo and reach the portal blood both as aglycones and as glucuronide and sulfate conjugates in humans.

Level of zearalenone in blood serum and lesions in ovarian follicles of sexually immature gilts in the course of zearalenone micotoxicosis.

The aim of the study was to determine how a low dose of zearalenone applied orally for eight days influences the level of zearalenone (ZEN) and alpha-zearalenole in blood plasma and causes the occurrence of histopathological changes in the cells of the ovarian follicles in sexually immature gilts. The animals were divided into 2 groups (control, C; n = 4 and experimental, E; n = 4). The gilts from group E were treated daily with zearalenone at a dose of 200 microg/kg b.w. The level of zearalenone and alpha-zearalenole (ZON as the sum of the levels of both zearalenone and alpha-zearalenole) was measured daily. On day eight of the experiment the animals were sacrificed and their ovaries were taken for histopathological examination. The tissue sections obtained were HE- and PAS-stained according to McManus. The presence of PCNA antigen was also estimated. The highest concentration of ZON was noted on day 5 in group E (8.16 +/- 2.49 ng/ml). External estrus symptoms without standing reflex were observed in group E on day 4. In group C there were no pathological changes in the ovaries. In group E, a few ovarian follicles were found, but they were located in the cortical layer. They were filled with a liquid substance rich in protein and without the granulosa layer. There was disintegration with apoptotic-like changes of the PCNA-negative cells in the granulosa layer of single mature follicles. On day 4 the dose of zearalenone caused disturbances in the process of development and maturation of some of the best developed ovarian follicles. This probably occurred through the activation of on apoptosis-like process of the granulosa cells with simultaneous manifestation of estrus without standing reflex.

Kinetics and metabolism of zearalenone in young female pigs.

The fate of a single bolus of the Fusarium mycotoxin zearalenone (ZON) given intravenously to pigs was followed up. Pigs were equipped with duodenal re-entrant cannulas, post-valvular T-shape cannulas and with a urinary bladder balloon catheter. The animals were divided into three groups. Pigs of the control group were injected with ZON (Co), and pigs of the second group were also injected with ZON but their duodenal digesta was quantitatively exchanged for 12 h with corresponding pigs of the third group, not injected with ZON. Therefore, the second group had a disrupted entero-hepatic cycling of ZON (DEHC) and the third one had an induced entero-hepatic cycling of ZON (IEHC). The kinetic profile of ZON and its metabolites in plasma and their flow with urine, duodenal and ileal digesta and with faeces was examined over the next 72 h after the bolus was given. Eleven days later, pigs were slaughtered for collection of bile, urine and liver to analyse ZON residues. In all specimens examined, alpha-zearalenol (ZOL) was detected as the only metabolite of ZON. Kinetic evaluation of the plasma data revealed that the terminal elimination half-life of ZON was reduced from 2.63 h in pigs of Co-group to 1.1 h when EHC of ZON was disrupted for 12 h (DEHC-group). The maximum ZON concentration in plasma of pigs with the IEHC was found at 2.73 h after the bolus was given to their counterparts. The percentage of the alpha-ZOL- and ZON-area under the curves (AUC) estimated for the IEHC-group amounted to approximately 18% of the corresponding AUC of the Co-group which would suggest that a substantial proportion of both substances are re-cycled via entero-hepatic re-circulation. Cumulative recovery of ZON and alpha-ZOL, expressed as percentage of the ZON-bolus was characterized by a saturation kinetics in urine and duodenal digesta, and after 72 h, the respective values for Co-, DEH-, and IEHC-groups were 70%, 55% and 12%; and 35%, 22% and 11%. Faecal excretion started to increase steeply after 48 h and still continued to increase after 72 h when the cumulative excretion was 6%, 3% and 2% for Co-, DEHC- and IEHC-groups respectively. Fourteen days after the bolus injection, ZON and alpha-ZOL concentrations in bile, liver and urine were lower than the detection limits of the applied method. The results would suggest that within this period of time a massive single bolus of ZON is nearly completely eliminated from the body.

Metabolic profiles of the mycotoxin zearalenone and of the growth promoter zeranol in urine, liver, and muscle of heifers.

A group of five heifers were fed for 84 days with 2 kg of zearalenone-contaminated oats (1370 microg/kg) resulting in an average daily intake of 2740 microg of zearalenone per animal. In a parallel experiment five heifers were implanted with two 25 mg zeranol pellets, one at the beginning of the study and one after 42 days, and fed with 2 kg of "blank" control oats (79 microg/kg, daily intake = 158 microg). A third group of five animals were also fed with 2 kg of "blank" oats and served as control. Urine samples of all animals were collected every 5-6 days during the whole period of the study. Animals of all three groups were killed 84 days after the beginning of the feeding study. Tissue samples (back, femoral region, liver, and residues of implanted pellets) were taken during post-mortem investigations. The content of zearalenone and zeranol and their metabolites in urine and tissue samples was established by an analytical method combining solid-phase extraction and high-performance liquid chromatography-tandem mass spectrometry. Urinary excretion rates of zeralenone and zeranol were calculated from these results.

[Biotransformation of zearalenone].

The conversion of Zearalenone by some strains of microorganisms was investigated. When the selective strains of Rhodotorula sp., Arthrobacter sp., Saccharomyces sp., and Candida sp. were incubated by shaking or standing at 28 degrees C for 72 h with an alcoholic solution of Zearalenone as the substrate at a concentration of 2-10 mg/ml ethanol (50-100 micrograms/ml medium), it was readily converted to give Zearalenols, consisting either mainly of the alpha-isomer (e.g. 96% in case of Rhodotorula sp. and 84% in case of Arthrobacter sp. as determined by HPLC) or beta-isomer (e.g. 91% and 92% in Saccharomyces sp. and Candida sp., respectively). The structure of the product was confirmed by 13C-NMR, MS and HPLC.

Metabolism of some anabolic agents: toxicological and analytical aspects.

The metabolism of the animal growth promotants diethylstilbestrol, zeranol and 17 beta-trenbolone and of a few anabolizing steroids used in humans is briefly reviewed. The possible role of reactive metabolic intermediates in the toxicity of some anabolic agents is discussed. Analytical implications of the metabolism of anabolizing agents are described and examples of the analysis of metabolites by means of recently developed techniques are given. It is proposed to utilize the covalent binding of reactive metabolites of anabolic compounds to blood proteins such as haemoglobin and serum albumin for retrospective doping analysis.

Profiling of free and conjugated [3H]zeranol metabolites in pig plasma.

Extraction and high-performance liquid chromatographic (HPLC) procedures are described that permit the complete analysis of free and conjugated zeranol metabolites in plasma from pigs implanted with [3H]zeranol. Free metabolites (9.0%) are extracted and then analysed by radio-HPLC on a reversed phase C18 column. They are distributed between three compounds that have been identified by gas chromatography-mass spectrometry as taleranol, zeranol and zeralanone. Direct radio-HPLC of the pre-extracted, deproteinated and Sep-Pak C18-purified plasma on a reversed-phase C18 column using tetrabutylammonium as an ion-pairing agent showed four main peaks: one corresponds to a weakly retained unidentified compound(s) (20%) and the other three were identified as the taleranol, zeranol and zeralanone glucuro conjugates. However, the total recovery is only about 25% owing to strong affinity of this polar material for the plasma proteins. Enzymatic deconjugation of the pre-extracted plasma followed by radio-HPLC analysis of the freed metabolites led to a good recovery of the radioactivity (81.8%) and allowed the quantitation of the different metabolites. These preliminary results indicate that zeranol is metabolized in the pig following pathways similar to those in other tested species.

Distribution of zeranol in bovine tissues determined by selected ion monitoring capillary gas chromatography/mass spectrometry.

Bovine tissues, including liver, muscle, kidney, bile, serum, and urine, have been quantified by selected ion monitoring capillary gas chromatography/mass spectrometry to establish the distribution of the anabolic drug, zeranol, and its metabolites, taleranol and zearalanone, after administration of zeranol to 9 bovine animals. The method used to isolate, confirm, and quantify zeranol is undergoing validation by the United States Department of Agriculture, Food Safety Inspection Service (FSIS). Application of this method demonstrates utility in determining residue levels of zeranol in a variety of tissues with levels ranging over 4 orders of magnitude (i.e., 100 parts per trillion (ppt) to 1 part per million (ppm]. The analyte levels determined in this study complement previously reported pharmacokinetic data on the distribution of zeranol in addition to providing more specific information for taleranol and zearalanone. In this quantitative study it is shown that the liver is the main organ of deposition for zeranol, taleranol, and zearalanone, that taleranol is the main metabolite in the bovine, and that zeranol is efficiently eliminated.